


Cell and Gene Therapy Catapult and the UK ecosystem

Shirley Lam
Business Development Manager - Asia

The Catapult Network

- A long-term investment to **transform** the UK's ability to create new products and services
- Open up global opportunities for the UK and **generate sustained economic growth** for the future
- **Strategically located** at sites all over the UK



About us



Part of a **world-leading network** of technology and innovation centres



Provide access to unique technical **facilities** and **expertise** to help adopt, develop and exploit innovations



Bridge the gap between businesses and academic research



Established by Innovate UK as a **not-for profit**, independent centre

It is our vision for the **UK** to be a **global leader** in the development, delivery and commercialisation of cell and gene therapies.

Where **businesses can start, grow and confidently develop** these transformative therapies, delivering them to patients rapidly and effectively.

Our facilities



Development Centre

- 1,200m² purpose built centre
- Analytical characterisation
- Process development
- Viral vector
- Stem cell differentiation
- 10th floor collaboration laboratory



Manufacturing Centre

- 7,700m² facility designed specifically for cell and gene therapy manufacturing at scale
- 12 segregated cleanroom modules
- Secure collaborative model
- At the centre of the third largest CGT cluster globally
- Expanded QC capacity & capability



Manufacturing Innovation Centre

- 4,627m² facility to support national COVID-19 vaccine manufacturing
- Fully operational by Dec 2021 to meet immediate vaccines demand
- To become innovation centre for CGTs and develop technology transfer innovation


Our mission

Accelerate	Complement	Innovate	Facilitate
the commercialisation of innovations from research	industry and academia with unique technical facilities and expertise	in collaboration with academia and industry	operating in UK as a global centre; working with Government, the NHS and international regulators

← Cell and gene therapy specialists (>300) →

Development Centre	Manufacturing Centre	Manufacturing Innovation Centre
1,200m ² centre for industrialising cell and gene therapy manufacture	7,700m ² facility for cell and gene therapy manufacturing at scale	4,627m ² facility to develop technology transfer innovation for industrial scale CGT manufacture
Industrialisation	Regulatory and clinical	Engagement
<ul style="list-style-type: none"> Process development Analytical development Manufacturing systems Supply chain 	<ul style="list-style-type: none"> Regulatory Non-clinical safety Clinical delivery Programme management 	<ul style="list-style-type: none"> Collaboration formation Intellectual property and patent Health economics Reimbursement

Strategic roadmap



The UK cell and gene therapy ecosystem



UK retains largest share of companies in Europe

- UK, Israel and Switzerland account for 40% of companies in Europe
- 70+ cell and gene therapy companies operating in the UK
 - 57 headquartered in the UK
 - 15 international companies with a UK presence


Companies split by technology

109 Gene Therapy 

142 Cell Therapy 

39 Tissue Engineering/ Biomaterials 

237+ Regenerative medicine / advanced therapies companies based in Europe and Israel




UK now accounts for 12% of global ATMP trials


In Europe between 1 January 2014 - 30 June 2019: the UK (112), Spain (102), and France (101) initiated the highest number of new ATMP clinical trials, followed by Germany (83) and Italy (66).

Now 127 ongoing ATMP clinical trials in the UK

CGT Catapult Clinical Trials Database
January 2020




The rapidly growing UK cell and gene therapy industry



The UK cell and gene therapy ecosystem

The UK has become the go-to place for cell and gene therapy development and boasts a complete cell and gene therapy ecosystem. CGT Catapult is facilitating the growth of the UK ecosystem by working with industry, the research base, Government, the NHS, industry associations and international organisations.



Stevenage Advanced Therapies Campus – 3rd Largest CGT Cluster Globally



£1.2bn

total investment into the campus since 2013

£944m

investment into CGT companies


30%

campus tenants are CGT companies (14/47)


5

CGT developers located at the Manufacturing Centre (out of 8 on campus)

Total investment into the Stevenage Advanced Therapies Campus
Cumulative investment - £m



The Advanced Therapy Treatment Centres network



- Develop and deliver systems for the routine delivery of these disruptive therapies.
- Disseminating the learnings and systems from the ATTC clinical centres to enable more widespread adoption of these innovative therapies across the NHS.
- **64 partners** – true collaboration between NHS, industry and academia.
- **200 – 250 people** working on the programme.
- Working in collaboration with London Advanced Therapies.

Coordinated by

ATAC Advanced Therapies Apprenticeship Community


- Established by CGT Catapult and MMIP
- £1.5M award from Industrial Strategy Challenge Fund
- First advanced therapies apprenticeship programme
- Aims to provide the skills required to fuel industry growth
- First cohort recruited in September 2018

ATAC impact:

111 apprentices
have now been employed

32 companies
have hired apprentices and formed the Advanced Therapies Apprenticeship Community

10 programmes
have been developed to provide the skills the industry needs



CATAPULT

Cell and Gene Therapy

12th Floor Tower Wing
Guy's Hospital
Great Maze Pond
London SE1 9RT
+44 (0)20 3728 9500
info@ct.catapult.org.uk
ct.catapult.org.uk
Twitter: @Catapult

Cell and Gene Therapy Catapult is a trading name of Cell Therapy Catapult Limited, registered in England and Wales under company number 07964711, with registered office at 12th Floor Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT. VAT number 154 4214 33.

